REFERENCES
1. Bergeron A, Rea D, Levy V, et al. Lung abnormalities after
dasatinib treatment for chronic myeloid leukemia: a case series.Am J Respir Crit Care Med. 2007; 176(8): 814–818. DOI:
10.1164/rccm.200705-715CR.
2. Medeiros BC, Possick J, Fradley M. Cardiovascular,
pulmonary, and metabolic toxicities complicating tyrosine kinase
inhibitor therapy in chronic myeloid leukemia: Strategies for
monitoring, detecting, and managing. Blood Rev. 2018; 32(4):
289–299. DOI: 10.1016/j.blre.2018.01.004.
3. Cortes JE, Apperley JF, DeAngelo DJ, et al. Management of
adverse events associated with bosutinib treatment of chronic-phase
chronic myeloid leukemia: expert panel review. J Hematol Oncol.2018; 11(1): 143. DOI: 10.1186/s13045-018-0685-2.
4. Gourd E, Bosutinib: more effective than imatinib in CML.Lancet Oncol. 2017; 18(12): e716. DOIi:
10.1016/s1470-2045(17)30840-9.
5. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al.
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia:
Results From the Randomized BFORE Trial. J Clin Oncol. 2018;
36(3): 231-237. DOI: 10.1200/jco.2017.74.7162.
6. Network NCC. Chronic Myeloid Leukemia (Version 3.2020).
2020;
https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf.
Accessed 3/7/2020.
7. Moguillansky NI, Fakih HAM, Wingard JR. Bosutinib induced
pleural effusions: Case report and review of tyrosine kinase inhibitors
induced pulmonary toxicity. Respir Med Case Rep. 2017; 21:
154–157. DOI: 10.1016/j.rmcr.2017.05.003.
8. Riou M, Seferian A, Savale L, et al. Deterioration of
pulmonary hypertension and pleural effusion with bosutinib following
dasatinib lung toxicity. Eur Respir J. 2016; 48(5): 1517–1519.
DOI: 10.1183/13993003.01410-2016.
9. Brummendorf TH, Cortes JE, Khoury HJ, et al. Factors
influencing long-term efficacy and tolerability of bosutinib in chronic
phase chronic myeloid leukaemia resistant or intolerant to imatinib.Br J Haematol. 2016;172(1):97–110. doi: 10.1111/bjh.13801.
10. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and
efficacy of bosutinib (SKI-606) in chronic phase Philadelphia
chromosome-positive chronic myeloid leukemia patients with resistance or
intolerance to imatinib. Blood. 2011;118(17):4567–4576. doi:
10.1182/blood-2011-05-355594.
11. Steegmann JL, Baccarani M, Breccia M, et al. European
LeukemiaNet recommendations for the management and avoidance of adverse
events of treatment in chronic myeloid leukaemia. Leukemia.2016;30(8):1648–1671. doi: 10.1038/leu.2016.104.
12. Jutant EM, Meignin V, Montani D, Tazi A, Rousselot P,
Bergeron A. Bosutinib-related pneumonitis. Eur Respir J.2017;50(3). doi: 10.1183/13993003.00930-2017.
13. Gambacorti-Passerini C, Brummendorf TH, Kim DW, et al.
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia
after imatinib resistance or intolerance: Minimum 24-month follow-up.Am J Hematol. 2014;89(7):732–742. doi: 10.1002/ajh.23728.
14. Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al.
Long-term efficacy and safety of bosutinib in patients with advanced
leukemia following resistance/intolerance to imatinib and other tyrosine
kinase inhibitors. Am J Hematol. 2015;90(9):755–768. doi:
10.1002/ajh.24034.
15. Gora-Tybor J, Medras E, Calbecka M, et al. Real-life
comparison of severe vascular events and other non-hematological
complications in patients with chronic myeloid leukemia undergoing
second-line nilotinib or dasatinib treatment. Leuk Lymphoma.2015;56(8):2309–2314. doi: 10.3109/10428194.2014.994205.
16. Zhang P, Huang J, Jin F, Pan J, Ouyang G. Imatinib-induced
irreversible interstitial lung disease: A case report. Medicine
(Baltimore). 2019;98(8):e14402. doi: 10.1097/md.0000000000014402.
17. Guignabert C, Phan C, Seferian A, et al. Dasatinib induces
lung vascular toxicity and predisposes to pulmonary hypertension.J Clin Invest. 2016;126(9):3207–3218. doi: 10.1172/jci86249.
18. Brixey AG, Light RW. Pleural effusions due to dasatinib.Curr Opin Pulm Med. 2010;16(4):351–356. doi:
10.1097/MCP.0b013e328338c486.
19. Garcia-Gutierrez V, Hernandez-Boluda JC. Tyrosine Kinase
Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety.Front Oncol. 2019;9:603. doi: 10.3389/fonc.2019.00603.
20. Peerzada MM, Spiro TP, Daw HA. Pulmonary toxicities of
tyrosine kinase inhibitors. Clin Adv Hematol Oncol.2011;9(11):824–836.
21. Yamamoto C, Nakashima H, Ikeda T, et al. Analysis of the
cost-effectiveness of treatment strategies for CML with incorporation of
treatment discontinuation. Blood Adv. 2019;3(21):3266–3277. doi:
10.1182/bloodadvances.2019000745.
22. Legros L, Nicolini FE, Etienne G, et al. Second tyrosine
kinase inhibitor discontinuation attempt in patients with chronic
myeloid leukemia. Cancer. 2017;123(22):4403–4410. doi:
10.1002/cncr.30885.
23. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of
imatinib in patients with chronic myeloid leukaemia who have maintained
complete molecular remission for at least 2 years: the prospective,
multicentre Stop Imatinib (STIM) trial. Lancet Oncol.2010;11(11):1029–1035. doi: 10.1016/s1470-2045(10)70233-3.